BR112023005370A2 - Composições e métodos para aumentar função das células-tronco - Google Patents
Composições e métodos para aumentar função das células-troncoInfo
- Publication number
- BR112023005370A2 BR112023005370A2 BR112023005370A BR112023005370A BR112023005370A2 BR 112023005370 A2 BR112023005370 A2 BR 112023005370A2 BR 112023005370 A BR112023005370 A BR 112023005370A BR 112023005370 A BR112023005370 A BR 112023005370A BR 112023005370 A2 BR112023005370 A2 BR 112023005370A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell function
- stem cell
- compositions
- methods
- enhance stem
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 5
- 230000003915 cell function Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 abstract 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 235000020956 nicotinamide riboside Nutrition 0.000 abstract 1
- 239000011618 nicotinamide riboside Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 229930186301 urolithin Natural products 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20198620 | 2020-09-28 | ||
| PCT/EP2021/076654 WO2022064061A1 (en) | 2020-09-28 | 2021-09-28 | Compositions and methods for increasing stem cell function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005370A2 true BR112023005370A2 (pt) | 2023-05-09 |
Family
ID=72665073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005370A BR112023005370A2 (pt) | 2020-09-28 | 2021-09-28 | Composições e métodos para aumentar função das células-tronco |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240010981A1 (https=) |
| EP (1) | EP4217471A1 (https=) |
| JP (1) | JP2023543149A (https=) |
| CN (1) | CN116234900A (https=) |
| AU (1) | AU2021348257A1 (https=) |
| BR (1) | BR112023005370A2 (https=) |
| CA (1) | CA3188629A1 (https=) |
| WO (1) | WO2022064061A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3246412A1 (en) * | 2022-03-22 | 2023-09-28 | Amazentis Sa | COMPOSITIONS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1998005635A1 (en) | 1996-08-07 | 1998-02-12 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| EP2995948A1 (en) * | 2014-09-09 | 2016-03-16 | Ecole Polytechnique Federale de Lausanne (EPFL) | Methods and compounds useful in hematopoietic stem cell medicine |
| CN104830772A (zh) * | 2015-05-28 | 2015-08-12 | 深圳富利鑫健康产业发展有限公司 | 一种造血干细胞培养基及其应用和干细胞培养方法 |
| EP3393467B1 (en) * | 2015-12-24 | 2020-07-01 | Amazentis SA | Compositions comprising nicotinamide riboside and a urolithin |
| JP7677893B2 (ja) * | 2019-01-18 | 2025-05-15 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 幹細胞機能を向上させるための薬剤及び方法 |
| US20220168271A1 (en) * | 2019-03-29 | 2022-06-02 | Societe Des Produits Nestle S.A. | Compositions and methods for increasing t cell function |
-
2021
- 2021-09-28 BR BR112023005370A patent/BR112023005370A2/pt unknown
- 2021-09-28 WO PCT/EP2021/076654 patent/WO2022064061A1/en not_active Ceased
- 2021-09-28 CN CN202180063424.0A patent/CN116234900A/zh active Pending
- 2021-09-28 AU AU2021348257A patent/AU2021348257A1/en active Pending
- 2021-09-28 EP EP21786140.0A patent/EP4217471A1/en active Pending
- 2021-09-28 US US18/246,744 patent/US20240010981A1/en active Pending
- 2021-09-28 CA CA3188629A patent/CA3188629A1/en active Pending
- 2021-09-28 JP JP2023515678A patent/JP2023543149A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023543149A (ja) | 2023-10-13 |
| EP4217471A1 (en) | 2023-08-02 |
| WO2022064061A1 (en) | 2022-03-31 |
| AU2021348257A1 (en) | 2023-03-02 |
| CN116234900A (zh) | 2023-06-06 |
| US20240010981A1 (en) | 2024-01-11 |
| CA3188629A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021015887A8 (pt) | Método para criopreservação de célula-tronco, população de células-tronco, composição de criopreservação, uso de nac, e kit de criopreservação | |
| BR112015020098A2 (pt) | método e composição para coloração e processamento de amostras | |
| BR112015001601A2 (pt) | células de levedura tendo curso de tca redutor de piruvato em succinato e superexpressão de uma enzima transidrogenase nad(p)+ exógena | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| CL2023001860A1 (es) | Composiciones y métodos para reducir hla-a en una célula | |
| BR122013008030B8 (pt) | método para produzir células eritroides e método para produzir um produto sanguíneo | |
| AR111835A1 (es) | Composiciones estables de inoculantes que comprenden aceites vegetales metilados | |
| BR112017011067A2 (pt) | cepas e métodos para a partição de energia em ruminantes | |
| BR112021017890A2 (pt) | Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana | |
| BR112022004757A2 (pt) | Composições de hidrolizado de proteína microbiana e métodos para fazer as mesmas | |
| BR112016027867A2 (pt) | composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, de carboidrato, para reduzir o índice glicêmico e para inibir a elevação do nível de açúcar, composição cosmética, uso da composição de fibra e composição | |
| BR112015023425A2 (pt) | método e composição para coloração e processamento de uma amostra de urina | |
| BR112014009837A8 (pt) | uso eficaz da levedura e extrato de levedura | |
| BR112021019349A2 (pt) | Células-tronco preparadas altamente funcionais | |
| BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| SV2017005416A (es) | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados | |
| BR112013026501A2 (pt) | métodos para preparar um oócito, de fertilização in vitro, e para aumentar a capacidade de geração de atp de um oócito, oócito, e, composição | |
| BR112021024657A2 (pt) | Célula de bacillus não esporulada, uso da referida célula, oligossacarídeo fucosilado, bem como o método para a produção e uso do mesmo e composição nutricional | |
| BR112017016077A2 (pt) | ?composição e método para uso no aumento da eficácia do enxerto de células-tronco hematopoiéticas após transplante? | |
| BR112022007950A2 (pt) | Integração direcionada no locus de alfa-globina em células-tronco e células progenitoras hematopoiéticas humanas | |
| BR112012012960A2 (pt) | supositório para administração retal, vaginal ou uretral e seus usos. | |
| BR112023005370A2 (pt) | Composições e métodos para aumentar função das células-tronco | |
| WO2022026933A3 (en) | In vitro differentiation of pancreatic endocrine cells | |
| BR112022019432A2 (pt) | Terapia de aumento mitocondrial |